Heron Therapeutics Q3 net revenue falls 7.8%, to sell all assets to CorMedix
CRMD•Heron Therapeutics' third-quarter net revenue fell 7.8% year over year to $35.3 million. The company agreed to sell substantially all its assets to CorMedix, pending shareholder approval.
1. Revenue declines
Heron Therapeutics reported third-quarter net revenue of $35.25 million, down 7.8% year over year. Acute care product revenue, including ZYNRELEF and APONVIE, increased, while oncology supportive care revenue fell, driven by lower CINVANTI sales and the end of SUSTOL commercial sales.
2. Asset sale and outlook
The company agreed to sell substantially all its assets to CorMedix Therapeutics, pending shareholder approval. Heron withdrew its full-year 2026 financial guidance in August and is not providing guidance now.
